Immune Checkpoint Add-Ons to BCG: No Slam Dunk – Medscape

Written by

admin

in

  1. Immune Checkpoint Add-Ons to BCG: No Slam Dunk  Medscape
  2. ESMO: Results for AZ’s Imfinzi in early bladder cancer type suggest it measures up to Pfizer candidate  Fierce Pharma
  3. ESMO 2025 | POTOMAC supports add-on durvalumab for high-risk NMIBC  springermedicine.com
  4. Adding atezolizumab to BCG does not improve EFS in BCG-naïve NMIBC  Urology Times
  5. Andrea Necchi: The Results of POTOMAC trial are out in The Lancet  Oncodaily

Continue Reading

More posts